Cytodyn Inc (CYDY)

[CTMedic]

The process of data verification, database locking, unblinding and analysis takes time.

In the case of Novartis:

RESULTS TOOK 61 DAYS.

WE ARE NOW AT 7.



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160984459

I am very, very anxious to see results.

I believe investors, the media, the FDA and a few sick patients are as well.

I hope that Cytodyn and Amarex substantially quicker at releasing results than was Norvartis.

Quote:

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 432 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Actual Study Start Date : May 2, 2020
Actual Primary Completion Date : October 17, 2020
Actual Study Completion Date : October 17, 2020


https://clinicaltrials.gov/ct2/show/NCT04362137?term=NCT04362137&draw=2&rank=1

I retrieved my fancy calculator and made a disheartening discovery.

With the trial ending October 17 and the results not released until December 14, 61 full days passed before these disappointing results were released.

CD12 completed January 13 (28 days after full enrollment date of December 16

Quote:
The CD12 trial completed enrollment with 394 patients on December 16

https://www.cytodyn.com/investors/news-events/press-releases/detail/493/fda-provides-guidance-for-adding-an-open-label-extension-to

Certainly you should not be worried for another (61-3) 58 days.

Check back in March!!

Whataboutdat? [/quote]